Andrew Waters
Assistant Professor University of Cincinnati Cancer Center
Seminars
Tuesday 16th September 2025
Workshop A – Debating Pan-RAS vs Pan-KRAS Inhibitors to Achieve Good Balance Between Efficacy & Toxicity for Treating Hard-to-Target Cancers
9:30 am
With the field continuing to strive to find effective, durable treatments for hard-to-target cancers such as pancreatic and colorectal cancers which contain a variety of RAS mutations. This session will engage participants in a debate and explore whether pan-RAS or pan-KRAS inhibitors offer the best balance between efficacy and toxicity, gain insights into the potential of this transformative approach for targeting multiple mutations and treating more patients.
This workshop will discuss:
- How to spare targeting of wild-type HRAS and NRAS by leveraging more specific pan-KRAS inhibitors
- How to improve therapeutic benefit by broadening the scope with pan-RAS inhibitors to treat a wider population of patients
- Are the early clinical successes of pan-RAS inhibitors more promising than initially assumed, or do pan-KRAS inhibitors still hold the edge in clinical development due to their specificity?
Thursday 18th September 2025
Analyzing Resistance to RAS Inhibitors to Improve Therapeutic Design for Achieving Greater Durability of Responses
11:30 am
- Showcasing comprehensive profiling of resistance mechanisms which arise from RAS inhibitor treatment
- Generating resistance cell lines to identify acquired resistance mechanisms to KRAS inhibitors
- Evaluating molecular consequences and resistance mechanisms of direct KRAS Q61H-selective inhibitors
